NCT06082167: Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- State
- Under way
- Phase
- Phase 2 and Phase 3
- People
- 600 planned
- Started
- 7 Jun 2024
- Primary completion
- Aug 2028
- Arms
- Zanzalintinib + Pembrolizumab
- Results
- None posted
- 13 Oct 2023: Trial registered
- 7 Jun 2024: Trial started